A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
A performance measure for rating the ability of a person to perform usual activities, evaluating a patient's progress after a therapeutic procedure, and determining a patient's suitability for therapy. It is used most commonly in the prognosis of cancer therapy, usually after chemotherapy and customarily administered before and after therapy. It was named for Dr. David A. Karnofsky, an American specialist in cancer chemotherapy.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Antibodies produced by a single clone of cells.
The return of a sign, symptom, or disease after a remission.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A cell line derived from cultured tumor cells.
Enzymes that are part of the restriction-modification systems. They are responsible for producing a species-characteristic methylation pattern, on either adenine or cytosine residues, in a specific short base sequence in the host cell's own DNA. This methylated sequence will occur many times in the host-cell DNA and remain intact for the lifetime of the cell. Any DNA from another species which gains entry into a living cell and lacks the characteristic methylation pattern will be recognized by the restriction endonucleases of similar specificity and destroyed by cleavage. Most have been studied in bacterial systems, but a few have been found in eukaryotic organisms.
Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Prosthetic replacements for arms, legs, and parts thereof.
Primary and metastatic (secondary) tumors of the brain located above the tentorium cerebelli, a fold of dura mater separating the CEREBELLUM and BRAIN STEM from the cerebral hemispheres and DIENCEPHALON (i.e., THALAMUS and HYPOTHALAMUS and related structures). In adults, primary neoplasms tend to arise in the supratentorial compartment, whereas in children they occur more frequently in the infratentorial space. Clinical manifestations vary with the location of the lesion, but SEIZURES; APHASIA; HEMIANOPSIA; hemiparesis; and sensory deficits are relatively common features. Metastatic supratentorial neoplasms are frequently multiple at the time of presentation.
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).
A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.
A publication issued at stated, more or less regular, intervals.
Individual's rights to obtain and use information collected or generated by others.
A quantitative measure of the frequency on average with which articles in a journal have been cited in a given period of time.
The use of statistical methods in the analysis of a body of literature to reveal the historical development of subject fields and patterns of authorship, publication, and use. Formerly called statistical bibliography. (from The ALA Glossary of Library and Information Science, 1983)
"The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.
The evaluation by experts of the quality and pertinence of research or research proposals of other experts in the same field. Peer review is used by editors in deciding which submissions warrant publication, by granting agencies to determine which proposals should be funded, and by academic institutions in tenure decisions.
Brain (recurrent glioblastoma)[edit]. There is a phase I/II study at the Mayo Clinic[32] of sorafenib and CCI-779 (temsirolimus ... Clinical trial number NCT00329719 for "Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma" at ... for recurrent glioblastoma. Desmoid tumor (aggressive fibromatosis)[edit]. A study performed in 2011 showed that Sorafenib is ... On November 22, 2013, sorafenib was approved by the FDA for the treatment of locally recurrent or metastatic, progressive ...
Two earlier clinical studies had suggested a benefit of TTFields treatment in recurrent glioblastoma, but definitive ... and evaluated efficacy of this approach in patients with recurrent glioblastoma. This trial was the primary basis for ... phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma". ... Israel and multiple countries in Europe for the treatment of recurrent glioblastoma. These devices generate electromagnetic ...
September 2015). "Phase II study of PX-866 in recurrent glioblastoma". Neuro-Oncology. 17 (9): 1270-4. doi:10.1093/neuonc/ ... In Sept 2015 as Phase 2 trial for recurrent glioblastoma reported not meeting its primary endpoint. Vanhaesebroeck B, Leevers ...
... a new treatment option being tested clinically for recurrent glioblastoma". Translational Cancer Research. 6 (S7): S1239-S1243 ... TIC10 (also known as ONC201) could cross the blood-brain barrier and treat glioblastoma brain cancer in mice. Glioblastoma is a ... administered every three weeks in recurrent glioblastoma". Oncotarget. 8 (45): 79298-79304. doi:10.18632/oncotarget.17837. ISSN ... clinic at Massachusetts General Hospital and New York University with some evidence of response in patients with glioblastoma. ...
Research has shown reduction in tumor growth in mice and rats with glioblastoma. This drug was specifically designed to treat ... "ANG1005 in Patients With Recurrent High-Grade Glioma". clinicaltrials.gov. "Angiochem's ANG1005 Shows Clinical Benefit and ... In 2014, paclitaxel trevatide received orphan drug designation from FDA for the treatment of glioblastoma multiform As of ... "Angiochem's ANG1005 Received Orphan Drug Designation from FDA for the Treatment of Glioblastoma multiform , Angiochem: Peptide- ...
"Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)" (PDF). 3 March 2016. ... In the United States temozolomide is indicated for the treatment of adults with newly diagnosed glioblastoma multiforme ... Sasmita AO, Wong YP, Ling AP (February 2018). "Biomarkers and therapeutic advances in glioblastoma multiforme". Asia-Pacific ... In the European Union temozolomide is indicated for adults with newly diagnosed glioblastoma multiforme concomitantly with ...
The FDA granted accelerated approval for the treatment of recurrent glioblastoma multiforme in May 2009. A 2018 Cochrane review ... "Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: ... and glioblastoma multiforme where it failed to improve overall survival. Bevacizumab has been investigated as a possible ... For cancer it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and ...
A formal trial of the CUSP9 protocol in recurrent glioblastoma [ClinicalTrials.gov Identifier: NCT02770378] in Ulm Germany was ... treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, ... CUSP9 is a treatment specifically targeted to glioblastoma that adds to a traditional cancer cell killing drug, temozolomide, ... The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 ...
"Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial". Neuro-Oncology. 16 ... GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma Bloch O, Crane CA, ...
"A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma ... Adegramotide (DSP-7888) is an experimental drug intended for treatment of glioblastoma multiforme. It is a peptide vaccine ...
... her glioblastoma diagnosis returned in 2012. With recurrent glioblastoma, Lipscomb became the first patient in Gromeier's phase ... Donna Clegg, a 60-year-old social worker from Idaho, was the 14th patient in the trial (also facing a glioblastoma diagnosis). ... Phase I trials in glioblastoma (GBM, one of the most deadly brain cancers) results have been very promising. The traditional ... In 2011, 20-year-old nursing student Stephanie Lipscomb was diagnosed with glioblastoma, as doctors found a tennis-ball-sized ...
... is a monoclonal antibody designed for the treatment of recurrent glioblastoma multiforme. ...
Phase II studies were able to demonstrate that cilengitide as a potential monotherapy in patients with recurrent glioblastoma ... in recurrent glioblastoma multiforme". Journal of Clinical Oncology. 26 (34): 5610-7. CiteSeerX 10.1.1.688.8987. doi:10.1200/ ... "Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment ... In a phase I/IIa study, the addition of cilengitide to the standard of care for newly diagnosed glioblastoma (surgical ...
May 2002). "Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme ...
EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma." ... his research at the Translational Center of Excellence in the Abramson Cancer Center focuses on Glioblastoma Multiforme, ... in glioblastoma. "Combining CAR T cells with existing immunotherapies may overcome resistance in glioblastomas". https://www. ... ". "CAR T-cell therapy 'quite promising' for glioblastoma". "Combining CAR T cells with existing immunotherapies may overcome ...
"Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Recurrent Glioblastoma - Press ... "Phase 1/2 Study of Investigational Hypoxia-Targeted Drug, TH-302, and Bevacizumab in Recurrent Glioblastoma Following ... "Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma - Press release ...
"Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First ... "Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and ... "Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First ... Glioblastoma multiforme is the most common and deadly brain tumor in adults, but only affects 10,000-17,000 people in the US. ...
The diagnostic utility of this latter category is uncertain as these tumors may behave either like glioblastoma or grade III ... Recurrent tumors are generally treated with more aggressive chemotherapy and radiation therapy. Recently, stereotactic surgery ... Anderson K. and Lindsey W., "What is the optimal length of treatment with Temodar (temozolomide) for glioblastoma?", Online at ... The updated WHO guidelines published in 2007 recommends classifying such tumors for the time being as 'glioblastoma with ...
... by Tocagen and as of July 2017 phase 2/3 trials were underway for recurrent astrocytoma and recurrent high grade glioblastoma. ... Strebe, JK; Lubin, JA; Kuo, JS (December 2016). ""Tag Team" Glioblastoma Therapy: Results From a Phase 1 Trial of Toca 511 and ... and the FDA had granted it Breakthrough Therapy Designation and FDA Fast Track designation for recurrent HGG, and an orphan ... 5-Fluorocytosine for Recurrent High-Grade Glioma". Neurosurgery. 79 (6): N18-N20. doi:10.1227/01.neu.0000508605.38694.fd. PMID ...
... suggesting it plays a role in conferring radioresistance to glioblastoma and in the development of recurrent glioblastoma. ... leads to substantial cell deaths and as a result has been proposed as a drug target in the treatment of glioblastoma. It has ... a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency". Oncotarget. 8 ... "Acid ceramidase confers radioresistance to glioblastoma cells". Oncology Reports. 38 (4): 1932-40. doi:10.3892/or.2017.5855. ...
In 2009, Avastin gained its fifth approval for treatment of glioblastoma multiforme, and sixth approval for the treatment of ... In 2006, also approved for locally advanced, recurrent or metastatic non-small cell lung cancer. In 2008, accelerated approval ...
"Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma". Journal of Cancer ...
For recurrent high-grade glioblastoma, recent studies have taken advantage of angiogenic blockers such as bevacizumab in ... In glioblastoma, the difference is larger. There, IDH1/2 wild-type glioblastoma have a median overall survival of 1 year, ... For people with recurrent GBM, when comparing temozolomide with chemotherapy, there may be an improvement in the time-to- ... found, in the glioblastomas without methylated MGMT promoters, that the level of microRNA miR-181d is inversely correlated with ...
... versus lomustine alone in patients with recurrent glioblastoma". Journal of Clinical Oncology. 31 (26): 3212-8. doi:10.1200/JCO ... "Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent ... of cediranib alone and cediranib with lomustine to the efficacy of lomustine alone in patients with recurrent glioblastoma. The ... "Combination of Targeted Drugs May Significantly Increase Progression-Free Survival in Women with Recurrent Ovarian Cancer, ...
Treatment of glioblastoma cells with TPEN showed that upregulation of ZIP9 in glioblastoma cells enhances cell migration in ... "Recurrent fusion transcripts detected by whole‐transcriptome sequencing of 120 primary breast cancer samples". Missing or empty ... "Recurrent fusion transcripts detected by whole‐transcriptome sequencing of 120 primary breast cancer samples". Genes, ... "Expression of the zinc importer protein ZIP9/SLC39A9 in glioblastoma cells affects phosphorylation states of p53 and GSK-3β and ...
Clinical trial number NCT00562419 for "CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination ... which has entered Phase II clinical trials investigating the treatment of glioblastoma in October 2007. The native FN3 scaffold ...
Clinical trial number NCT00562419 for "CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination ... The drug has entered Phase II clinical trials investigating the treatment of glioblastoma in October 2007. As of August 2012[ ...
... and operable recurrent intracranial neoplasms, including meningiomas, metastases, high-grade gliomas, and glioblastomas. In a ... Brachytherapy followed EBRT or surgery have been showed can improve the survival rate and local recurrent rate than EBRT or ... "Endoluminal high-dose-rate brachytherapy for early stage and recurrent esophageal cancer in medically inoperable patients". ... "High-dose-rate brachytherapy for previously irradiated patients with recurrent esophageal cancer". Radiation Medicine. 25 (8): ...
G-202 is also being evaluated in a Phase II clinical trial in glioblastoma patients with recurrent disease after surgery and/or ... in Patients With Recurrent or Progressive Glioblastoma - Full Text View - ClinicalTrials.gov". "Press Releases :: Inspyr ...
... since 2010 in a Phase I/II clinical trial for the potential treatment of recurrent high-grade glioma including glioblastoma ... Glioblastoma multiformeEdit. Main article: Glioblastoma multiforme. Glioblastoma multiforme (GBM) is the most aggressive (grade ... Giant-cell glioblastoma, Glioblastoma multiforme, Gliomatosis cerebri, Gliosarcoma, Hemangiopericytoma, Medulloblastoma, ... Standard therapy for glioblastoma multiforme consists of maximal surgical resection of the tumor, followed by radiotherapy ...
"PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma - Full ... a novel PDGFR Inhibitor for treatment of glioblastoma". Cancer Research. 71 (8 Supplement): 1111. doi:10.1158/1538-7445.am2011- ... "PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma" at ...
In solid tumors, a majority of gene mutations are not recurrent types,[48] and neither are the karyotypes.[40][42] These ... 2012). "Wnt activation is implicated in glioblastoma radioresistance". Lab. Invest. 92 (3): 466-473. doi:10.1038/labinvest. ... Many of the somatic evolutionary studies have traditionally been focused on clonal expansion, as recurrent types of changes can ...
... particularly for glioblastoma, but in other cancers and studies, no anti-tumour effect was seen. Taken together, results from ... It is diagnosed in a person having recurrent, unprovoked seizures. These occur when cortical neurons fire excessively, ...
"Entrez Gene: ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog ( ... An example of an advanced recurrent breast cancer with an ulcerating axillary mass ...
... s often are considered benign tumors that can be removed by surgery, but most recurrent meningiomas correspond to ... The metabolic phenotype of these benign recurrent meningiomas indicated an aggressive metabolism resembling that observed for ... A 2007 study of whether hydroxyurea has the capacity to shrink unresectable or recurrent meningiomas is being further evaluated ...
... in induction which have been found to be effective against recurrent disease. ...
January 2012). "Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma". Nature. 482 (7384 ... "Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma". Cell Reports. 7 (1): 104-12. ...
2009). „EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Research 69(24): 9211-9218".. line feed ... Miller CA, Settle SH, Sulman EP, Aldape KD, Milosavljevic A (2011). „Discovering functional modules by identifying recurrent ...
Within the TNM system, a cancer may also be designated as recurrent, meaning that it has appeared again after being in ... more commonly referred to as glioblastoma multiforme, is a universally fatal primary brain cancer most commonly seen in the 7th ...
10.8 (recurrent), 27.1 (+ X-ray). [41]. R2-0, Studsvik Medical AB, Sweden. 30 (2001-2007). BPA 900 mg/kg. 17.7 (primary). [47][ ... 2009). "Boron neutron capture therapy for newly diagnosed glioblastoma". Journal of Radiation Research. 50 (1): 51-60. Bibcode: ... 2006). "Motexafin-gadolinium taken up in vitro by at least 90% of glioblastoma cell nuclei". Clinical Cancer Research. 12 (1): ... 2008). "Survival benefit of boron neutron capture therapy for recurrent malignant gliomas". Journal of Neuro-Oncology. 91 (2): ...
... recurrent glioblastoma, and acute myeloid leukemia. Erismodegib was created by Novartis. It is a SMO antagonist that can induce ... The gain-of-function GLI1 transcription factor TGLI1 enhances expression of VEGF-C and TEM7 to promote glioblastoma ... Erismodegib has been effective in limiting the invasive potential of multiple cancer types including glioblastoma, prostate ... inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and ...
... occur almost exclusively in glioblastoma and can provide means to distinguish anaplastic astrocytoma from glioblastoma. ... development of a clinical tool and discovery of recurrent genomic alterations". Proc Natl Acad Sci U S A. 101 (4): 1039-44. doi ... studied 55 glioblastoma and 6 GBM cell lines using SNP array karyotyping. Acquired UPD was identified at 17p in 13/61 cases. A ... The importance of detecting acquired UPD (copy neutral LOH) in glioblastoma: Of patients with 17p abnormality, ~50% were ...
The EFS mRNA was also identified as differentially expressed in two of the three groups of glioblastoma multiforme as ... mild coagulation defects and propensity to recurrent bacterial and fungal infections, caused by incomplete phagocytosis due to ...
O6-BG was used clinically in combination with the alkylating agent temozolomide for glioblastoma, however the combination was ... 2005). "Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma". ... 2009). "Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults with Recurrent, Temozolomide-Resistant Malignant Glioma ... plus BCNU versus RT and BCNU alone and methylation status in newly-diagnosed glioblastoma (GBM) and gliosarcoma: Southwest ...
Though these changes are usually not recurrent, the mutations generally occur in exons 2 through 6 with exon 2 mutations being ... For example, PAX3 is expressed in cancers associated with neural tube-derived lineages, (e.g., glioblastoma), neural crest- ... "Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma". primary. Nature Genetics. 46 (7): 666-8. doi:10.1038/ng.2989. ... is an aggressive soft tissue sarcoma that occurs in children and is usually characterized by a recurrent t(2;13)(q35;q14) ...
The modified virus was also found to efficiently kill human glioblastoma tumour cell lines. The maraba virus, first identified ... in patients with recurrent malignant glioma". Gene Therapy. 7 (10): 859-66. doi:10.1038/sj.gt.3301184. PMID 10845724. ... From 1997 to 2003, strain HSV1716 was injected into tumours of patients with glioblastoma multiforme, a highly malignant brain ... in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer". Nature Medicine. 6 (8): 879- ...
Myles N (October 2017). "Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on ... from a glioblastoma multiforme cell line and localization of the G-CSF gene to chromosome band 17q21". Oncogene Research. 1 (3 ...
MVK Hyper-IgE recurrent infection syndrome; 147060; STAT3 Hyper-IgE recurrent infection syndrome, autosomal recessive; 243700; ... CYP1B1 Glioblastoma, somatic; 137800; ERBB2 Globozoospermia; 102530; GOPC Globozoospermia; 102530; SPATA16 Glomerulocystic ... benign recurrent intrahepatic, 2; 605479; ABCB11 Cholestasis, benign recurrent intrahepatic; 243300; ATP8B1 Cholestasis, ... acute recurrent, autosomal recessive; 268200; LPIN1 Myokymia with neonatal epilepsy; 606437; KCNQ2 Myopathy due to CPT II ...
In brain tumours, more specifically oligodendroglial tumours and glioblastomas, the ID4 gene has been shown to be expressed in ... a new recurrent [email protected] translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)". Blood. 111 (1): ... "TGene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme". Proceedings of the ...
For recurrent head and neck cancer requiring reirradiation, proton therapy is able to maximize a focused dose of radiation to ... Another Phase II Randomized Controlled Trial comparing photons versus protons for Glioblastoma concluded that patients at risk ... radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial". Journal of Hepatology. 74 (3): ... Re-irradiation is a potentially curative treatment option for patients with locally recurrent head and neck cancer. In ...
Suffering from recurrent headaches, her strict diet routine (she used to not eat anything from the night before her performance ... a mass in the right parietal lobe of her brain which turned out to be a giant cell glioblastoma. She underwent three brain ...
Patients with recurrent glioblastoma had dramatic improvement in response, progression-free survival, and overall survival ... Patients with recurrent glioblastoma have few treatment options, first author Henry Friedman, MD, of Duke University in Durham ... Patients with recurrent glioblastoma had dramatic improvement in response, progression-free survival (PFS), and overall ... "Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma" J Clin Oncol 2009; DOI: 10.1200/JCO.2008.19. ...
Amgen 386 for Recurrent Glioblastoma. The safety and scientific validity of this study is the responsibility of the study ... Amgen 386 for Recurrent Glioblastoma. Official Title ICMJE Phase I/II Study of Amgen 386 With and Without Bevacizumab for ... To determine the efficacy of AMG 386 in participants with recurrent glioblastoma (GBM) as measured by 6‐month progression‐free ... Phase II To determine the efficacy of AMG 386 plus bevacizumab in participants with recurrent glioblastoma (GBM) as measured by ...
Epothilone in Recurrent Glioblastoma Patients. The safety and scientific validity of this study is the responsibility of the ... Phase II Study: Systemic Treatment With iv ZK219477-Epothilone in Recurrent Glioblastoma Patients. ... Glioblastoma. Astrocytoma. Glioma. Neoplasms, Neuroepithelial. Neuroectodermal Tumors. Neoplasms, Germ Cell and Embryonal. ... Also patients with residual disease after surgery for recurrent GBM will be included ...
... Seema Nagpal,1,2 Griffith Harsh,3 and Lawrence ... "Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy," Neuro-Oncology, vol. 16, no ... Yoshitaka Narita, "Bevacizumab for glioblastoma," Therapeutics And Clinical Risk Management, vol. 11, pp. 1759-1765, 2015. View ... "The role of bevacizumab in the treatment of glioblastoma," Journal of Neuro-Oncology, 2017. View at Publisher · View at Google ...
Ketogenic Diet for Recurrent Glioblastoma (ERGO). The safety and scientific validity of this study is the responsibility of the ... ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014 Jun;44(6):1843-52. doi: 10.3892/ijo. ... To determine whether a mild ketogenic diet can influences quality of life and survival of patients with recurrent glioblastoma ... Glioblastoma. Astrocytoma. Glioma. Neoplasms, Neuroepithelial. Neuroectodermal Tumors. Neoplasms, Germ Cell and Embryonal. ...
... recurrent glioblastoma (GBM). Methods. This is a retrospective study of 40 adult patients with recurrent GBM treated between ... Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma. Seema Nagpal,1,2 Griffith Harsh,3 and Lawrence ... M. C. Chamberlain and S. K. Johnston, "Salvage therapy with single agent bevacizumab for recurrent glioblastoma," Journal of ... In May of 2009, the FDA approved the use of bevacizumab (BEV) for recurrent glioblastoma (GBM) based on imaging and clinical ...
... but her remission ended in 2014 when she was diagnosed with glioblastoma, the most aggressive form of brain cancer. Now shes ... but her remission ended in 2014 when she was diagnosed with glioblastoma, the most aggressive form of brain cancer. Now shes ... Immunotherapy clinical trial for glioblastoma. Thats when my neuro-oncologist, Barbara OBrien, M.D., told me about a clinical ... I was then diagnosed with glioblastoma, the most aggressive form of brain cancer. I started proton therapy for five weeks, ...
Metronomic Temozolamide in Patients With Recurrent Glioblastoma. Official Title ICMJE PHASE I-II TRIAL OF METRONOMIC ... Metronomic Temozolamide in Patients With Recurrent Glioblastoma. The recruitment status of this study is unknown. The ... TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Brief Summary Indication ... Subjects with glioblastoma at first relapse after surgery, radiotherapy and first-line temozolomide (TMZ). ...
A Phase II Study of Tivozanib in Recurrent Glioblastoma. Trial Phase:. Phase 2. Minimum Age:. 18 Years. Maximum Age:. N/A ... A Phase II Study of Tivozanib in Recurrent Glioblastoma. If you are willing to participate in this study, you will be asked to ... To determine the proportion of patients with recurrent glioblastoma (GBM) alive and progression free 6 months (PFR6) after ... Histologically confirmed glioblastoma that has progressed based on imaging or surgery. - Measurable disease. - No more than 3 ...
Researchers at Duke Cancer Institute report that an attack on glioblastoma brain tumor cells that uses a modified poliovirus is ... With traditional treatment, about half of glioblastoma patients see recurrent tumor growth within eight weeks. Two patients in ... Glioblastoma Multiforme. Glioblastomas are tumors that arise from astrocytes that make up the supportive tissue of the brain. ... "Current therapies for glioblastoma are limited because they cannot cross the blood-brain barrier and often do not specifically ...
An experimental gene therapy essentially doubled the overall survival of patients with recurrent glioblastoma compared to the ... An experimental gene therapy essentially doubled the overall survival of patients with recurrent glioblastoma compared to the ...
Phase II Study: Systemic Treatment With iv ZK219477-Epothilone in Recurrent Glioblastoma Patients. Trial Phase:. Phase 2. ... Study Population: 15 recurrent glioblastoma. patients previously treated by surgery, conventional radiotherapy and chemotherapy ... Phase II Study: Systemic Treatment With iv ZK219477-Epothilone in Recurrent Glioblastoma Patients ... 219477 in the treatment of pre-treated, recurrent GBM patients. Aim of the study: The. purpose of this single arm phase II ...
A literature overview on the feasibility and efficacy of the different irradiation modalities for recurrent glioblastoma along ... most patients with glioblastoma ultimately experience local progression/relapse. Re-irradiation has been poorly viewed in the ... Radiation Therapy for the Treatment of Recurrent Glioblastoma: An Overview. Dante Amelio * and Maurizio Amichetti. ... Amelio, D.; Amichetti, M. Radiation Therapy for the Treatment of Recurrent Glioblastoma: An Overview. Cancers 2012, 4, 257-280 ...
PCV chemotherapy for recurrent glioblastoma multiforme. A.C. Kappelle, T.J. Postma, M.J.B. Taphoorn, G.J. Groeneveld, M.J. van ... PCV chemotherapy for recurrent glioblastoma multiforme. A.C. Kappelle, T.J. Postma, M.J.B. Taphoorn, G.J. Groeneveld, M.J. van ... and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV ... Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol . 1999; 17: ...
... comment on the factors that influence treatment decisions in recurrent disease in patients with glioblastoma. ... Treatment Options in Recurrent Glioblastoma. Insights From:Susan C. Pannullo, MD, Weill Cornell Brain and Spine Center; Steven ... When a patient comes back with a recurrent glioblastoma, the question that comes to the multidisciplinary team of the radiation ... When a patient comes back with a recurrent glioblastoma, the question that comes to the multidisciplinary team of the radiation ...
Bevacizumab is a therapeutic drug used in treatment of recurrent glioblastoma to inhibit angiogenesis. Treatment response is ... In the current study we examine cerebral blood volume and blood flow characteristics in 45 recurrent glioblastoma patients ... Bevacizumab is a therapeutic drug used in treatment of recurrent glioblastoma to inhibit angiogenesis. Treatment response is ... MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma ...
... can help to control glioblastoma and/or gliosarcoma. Researchers also want to learn more about how much study drug is in ... A Phase II Study of BKM120 for Patients with Recurrent Glioblastoma and Activated PI3K Pathway. ... The goal of this clinical research study is to learn if BKM120 (buparlisib) can help to control glioblastoma and/or gliosarcoma ... 2 Cohort 2 2.1 Primary Objective To investigate the treatment efficacy of BKM120 in participants with recurrent GBM as measured ...
... Friday, June 2, 2017 Genetics & Stem Cells News ... "We are honored that our study for recurrent glioblastoma was selected for an oral presentation at ASCO," said Frank Tufaro, PhD ... DNX-2401 has been well tolerated in patients with recurrent glioblastoma and survival has been prolonged compared to other ... www.prnewswire.com/news-releases/dnatrix-to-present-results-of-dnx-2401-for-recurrent-glioblastoma-at-asco-2017-300467483.html ...
Poliovirus Vaccine Trial Shows Early Promise for Recurrent Glioblastoma. February 13, 2017. by Gady Goldsobel ... Home » Medical Breakthroughs » Poliovirus Vaccine Trial Shows Early Promise for Recurrent Glioblastoma ... With traditional treatment, about half of glioblastoma patients see recurrent tumor growth within eight weeks. ... "Current therapies for glioblastoma are limited because they cannot cross the blood-brain barrier and often do not specifically ...
... of treatment with the study drug in combination with bevacizumab versus bevacizumab alone in patients with glioblastoma. ... A study of DSP-7888 dosing emulsion in combination with bevacizumab in patients with recurrent or progressive glioblastoma ... effectiveness of treatment with DSP 7888 in combination with bevacizumab versus bevacizumab alone in patients with glioblastoma ...
Re-irradiation with proton therapy is a safe and effective treatment in patients with recurrent glioblastoma. Proton therapy ... Proton therapy re-irradiation preserves health-related quality of life in large recurrent glioblastoma J Cancer Res Clin Oncol ... Conclusions: Re-irradiation with proton therapy is a safe and effective treatment in patients with recurrent glioblastoma. ... aim of this study was to determine the effect of re-irradiation with active scanning proton therapy on recurrent glioblastoma ( ...
There is no standard treatment for recurrent glioblastoma multiforme (GBM). Retreatment with temozolomide (TMZ) is one ... Chen C, Xu T, Lu Y, Chen J, Wu S (2013) The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur J Neurol 20(2): ... There is no standard treatment for recurrent glioblastoma multiforme (GBM). Retreatment with temozolomide (TMZ) is one ... results of a phase I trial in patients with recurrent glioblastoma multiforme. ...
Pseudoprogression and radiation necrosis can appear similar to recurrent glioblastoma on MRI. So a false positive finding that ... About Glioblastoma Glioma, a type of tumor that starts in the brain and arises from glial cells, is a broad category of tumors ... Glioblastoma, a type of glioma, is the most common adult primary brain cancer. The current standard imaging modality used to ... Glioblastoma, the most common primary adult brain cancer, is rapidly life-threatening with most patients succumbing to the ...
A Phase II Study of Nivolumab plus Radiation Therapy and Bevacizumab for Recurrent Glioblastoma *. ... and bevacizumab are treatments used for people with recurrent glioblastoma (GBM). In this study, researchers want to see if ... Bevacizumab is often used in combination with radiation therapy as a treatment for patients whose glioblastoma grows during or ... Patients must have grade IV MGMT-methylated glioblastoma that has grown despite one prior regimen of treatment with radiation ...
... Sub- ... NovoTTF-100A alternating electric fields therapy for recurrent glioblastoma: An analysis of patient registry data.. Als ... for the treatment of recurrent glioblastomas. It emits alternating electric fields, at an intensity of 1 V/cm and a frequency ... as prescribed in the general clinical setting to patients with recurrent glioblastomas, offers favorable outcomes compared to ...
... can be used to generate a prediction model for stratifying treatment outcome among patients with recurrent glioblastoma prior ... can be used to generate a prediction model for stratifying treatment outcome among patients with recurrent glioblastoma prior ... quantitative magnetic resonance imaging features from the multiparametric tumors of 172 patients with recurrent glioblastoma ...
Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma Phase III ... Clinical trial for Glioblastoma Multiforme , Disease Progression , Relapse , ... For patients who underwent surgery for recurrent disease; (i)progressive or recurrent glioblastoma must be confirmed on ... Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma Phase III Are you eligible ...
Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting. ... Tolerability and survival in recurrent glioblastoma. Abstract Number: 2044. Session: Central Nervous System Tumors. Date and ... orally administered veledimex in patients with recurrent or progressive glioblastoma at the 2017 American Society of Clinical ...
VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients. Email ... Glioblastoma GBM Clinical Study Clinical Trial Immuno-oncology Immunotherapy Patient Dosing tumor VBI VBI Vaccines Biotech CMV ... low-dose patient cohort of the ongoing Phase 1/2a clinical study of VBI-1901 in recurrent Glioblastoma (GBM), the independent ... Glioblastoma is among the most common and aggressive malignant primary brain tumors in humans. In the U.S. alone, 12,000 new ...
Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent ... chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma ... chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma ... with recurrent GBM were treated\. PCB was administered as an oral dosage of 450 mg on days 1-2 and a total dose of 300 mg on ...
  • Preliminary data, presented at the upcoming 2013 Annual Meeting of the American Society of Clinical Oncology in Chicago (ASCO abstract #2094), previews the results of seven patients enrolled in the study whose tumors reoccurred despite traditional treatments for glioblastoma multiforme, the most common and aggressive brain tumor. (medindia.net)
  • The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. (neurology.org)
  • Despite different treatment options such as reoperation, reirradiation, gene therapy, immune therapy, and chemotherapy, no standard treatment regimen with proven effectiveness and acceptable toxicity is yet available for patients with recurrent glioblastoma multiforme (rGBM), and the prognosis remains poor. (neurology.org)
  • There is no standard treatment for recurrent glioblastoma multiforme (GBM). (springer.com)
  • Chen C, Xu T, Lu Y, Chen J, Wu S (2013) The efficacy of temozolomide for recurrent glioblastoma multiforme. (springer.com)
  • Glioblastoma multiforme (GBM) is a highly aggressive brain cancer with extremely poor prognostic outcome despite intensive treatment. (frontiersin.org)
  • LOS ANGELES--(July 30, 2013)-- ImmunoCellular Therapeutics, Ltd. ('ImmunoCellular') (NYSE MKT: IMUC) today announced initiation of a phase I clinical trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme (GBM). (fiercepharma.com)
  • Glioblastoma multiforme is the most common and deadly form of primary brain cancer. (spie.org)
  • Five patients with documented recurrences of glioblastoma multiforme were given continuous infusions of methotrexate delivered intratumorally using implantable catheters and subcutaneous refillable pumps. (elsevier.com)
  • Patients with recurrent glioblastoma multiforme (GBM) treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared. (scienceblog.com)
  • A prominent protein activated by inflammation is the key instigator that converts glioblastoma multiforme cells to their most aggressive, untreatable form and promotes resistance. (scienceblog.com)
  • Jim Black is fighting the meanest, most aggressive, most common kind of brain tumor in the United States: recurrent glioblastoma multiforme (GBM). (scienceblog.com)
  • Bevacizumab (BEV) is a key anti-angiogenic agent in the treatment for recurrent glioblastoma multiforme (GBM). (researchsquare.com)
  • However, to date, there are few reported outcomes from using IMRT, either alone or as a boost technique, for standard fractionation radiotherapy for glioblastoma multiforme (GBM). (biomedcentral.com)
  • Inclusion criteria for this retrospective chart review were pathological diagnosis of glioblastoma multiforme (WHO Grade IV) treated with IMRT using daily fractions between 1.8-2 Gy. (biomedcentral.com)
  • PURPOSE: This phase I trial is studying the side effects and best dose of viral therapy in treating patients with recurrent glioblastoma multiforme. (careacross.com)
  • I. To assess the safety and toxicity of intratumoral and resection cavity administration of an Edmonston's strain measles virus genetically engineered to produce CEA (MV-CEA) in patients with recurrent glioblastoma multiforme. (careacross.com)
  • NovoTTF-100A is a device and Bevacizumab is a study drug that have both been approved by the FDA (Food and Drug Administration) for use as monotherapy in treating glioblastoma multiforme. (careacross.com)
  • The purpose of this study was to evaluate the feasibility of procarbazine and CCNU chemotherapy for recurrent glioblastoma multiforme (GBM) with O 6 -methylguanine-DNA-methyltransferase (MGMT) promoter methylation. (cdc.gov)
  • Indicated for glioblastoma multiforme combined with radiotherapy. (medscape.com)
  • Glioblastoma multiforme (GBM) is the most common and most malignant of the glial tumors. (medscape.com)
  • Histopathologic slide demonstrating a glioblastoma multiforme (GBM). (medscape.com)
  • GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme. (news-medical.net)
  • The SAFE-trial: Safe surgery for glioblastoma multiforme: Awake craniotomy versus surgery under general anesthesia. (rug.nl)
  • Although doxorubicin (DOX) is an effective anti-cancer drug with cytotoxicity in a variety of different tumors, its effectiveness in treating glioblastoma multiforme (GBM) is constrained by insufficient penetration across the blood-brain barrier (BBB). (nature.com)
  • Glioblastoma multiforme (GBM) is the most common and aggressive form of malignant gliomas whose current standard of care involves surgical recession followed by chemotherapy and radiotherapy 1 , 2 . (nature.com)
  • Phosphatase and tensin homolog (PTEN) mutation in glioblastoma multiforme (GBM) patients causes abnormally high activity of the pathways of Phosphatidylinositide 3-kinases (PI3K), Protein Kinase B (AKT), and the mammalian target of rapamycin (mTOR) and is associated with unfavorable prognosis. (regionh.dk)
  • Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive type of cancer that begins within the brain. (wikipedia.org)
  • A TTField-generating device manufactured by the Israeli company Novocure is approved in the United States and Europe for the treatment of newly diagnosed and recurrent glioblastoma multiforme (GBM), and is undergoing clinical trials for several other tumor types. (wikipedia.org)
  • The purpose of this single arm phase II study is to evaluate safety and efficacy of ZK 219477 in the treatment of temozolomide pre-treated, recurrent GBM patients. (clinicaltrials.gov)
  • Standard treatment for glioblastoma includes resection, irradiation and temozolomide chemotherapy. (clinicaltrials.gov)
  • Subjects with glioblastoma at first relapse after surgery, radiotherapy and first-line temozolomide (TMZ). (clinicaltrials.gov)
  • Study Population: 15 recurrent glioblastoma patients previously treated by surgery, conventional radiotherapy and chemotherapy with temozolomide (TMZ. (knowcancer.com)
  • Johnson DR, O'Neill BP (2012) Glioblastoma survival in the United States before and during the temozolomide era. (springer.com)
  • Patients must have grade IV MGMT-methylated glioblastoma that has grown despite one prior regimen of treatment with radiation therapy and temozolomide. (mskcc.org)
  • Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. (virtualtrials.com)
  • The only FDA-approved standard-of-care drugs to treat glioblastoma are temozolomide, nitrosoureas, and bevacizumab. (tgen.org)
  • Bevacizumab (BEV) plus daily temozolomide (TMZ) as a salvage therapy have been recommended to recurrent glioma. (neurosurgery.directory)
  • The most common treatment options for recurrent GBM were combination repeat surgical resection with temozolomide or bevacizumab, monotherapy temozolomide or bevacizumab, and best supportive care. (neurosurgery.directory)
  • All patients previously had a de novo glioblastoma and following their initial resection received standard temozolomide and fractionated radiotherapy. (elsevier.com)
  • Patients with histologically confirmed glioblastoma or other grade IV malignant glioma (i.e. gliosarcoma, small cell glioblastoma, etc.), recurrent after prior external-beam fractionated radiotherapy and temozolomide chemotherapy. (careacross.com)
  • i,ii Patients with recurrent GBM typically have a median overall survival (mOS) of 6-7 months, and overall survival in patients who have failed temozolomide, bevacizumab or equivalent salvage chemotherapy, is approximately 3-5 months. (firstwordpharma.com)
  • Since the study of Stupp [ 1 ] in 2005, the standard treatment for patients with primary glioblastoma includes a concomitant and adjuvant chemotherapy with temozolomide. (beds.ac.uk)
  • However, no study investigated the impact of pretreatment with temozolomide on the efficacy of BCNU in the treatment of recurrent glioblastoma. (beds.ac.uk)
  • The BRAIN study was an open-label, multicenter, randomized, noncomparative Phase II study involving 167 patients with recurrent glioblastoma (rGBM) previously treated with temozolomide (TMZ) and RT. (avastin.com)
  • The most aggressive malignant primary brain tumor in adults, glioblastoma is usually fatal, despite aggressive therapy that typically includes surgery, radiotherapy, and chemotherapy. (medpagetoday.com)
  • Researchers at Duke Cancer Institute report that an attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study. (medindia.net)
  • With traditional treatment, about half of glioblastoma patients see recurrent tumor growth within eight weeks. (medindia.net)
  • one had recurrent tumor growth after two months, and another's condition declined after four months. (medindia.net)
  • Current therapies for glioblastoma are limited because they cannot cross the blood-brain barrier and often do not specifically attack the tumor. (medindia.net)
  • 3 Since then several studies have been published on PCV chemotherapy in patients with (recurrent) glioma, including various brain tumor histologies. (neurology.org)
  • DNX-2401 sets off a chain reaction of tumor cell killing by selectively replicating within glioblastoma cells (but not normal cells), causing tumor destruction and further spread of the oncolytic virus to adjacent tumor cells. (medindia.net)
  • Preclinical and pilot human studies of I-124-CLR1404 conducted under investigator-sponsored INDs have suggested remarkable specificity in malignant tumor and cancer stem cell uptake, and potential distinction between true tumor progression and pseudoprogression in patients with newly diagnosed or recurrent glioblastoma. (cnbc.com)
  • In recurrent GBM, a devastating CMV-associated tumor, patients have few effective treatment options, and we believe that VBI-1901 has the potential to stimulate immune responses critical to boosting anti-tumor immunity. (globenewswire.com)
  • PHOENIX, Ariz. - Oct. 27, 2017 - Several patients with recurring glioblastoma, a deadly brain cancer, survived for more than a year in a clinical trial believed to be the first to use comprehensive DNA and RNA sequencing of a patient's tumor to inform treatment for these patients in real-time. (tgen.org)
  • Fifteen of 16 glioblastoma patients in the study conducted at UCSF received TGen's genomics-informed treatment recommendations, in which the therapeutics suggested by a medical review panel (UCSF's Molecular Tumor Board) were matched to each patient's particular genetic code. (tgen.org)
  • ImmunoCellular is conducting a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. (fiercepharma.com)
  • MONTREAL , Nov. 19, 2010 /PRNewswire/ -- Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy. (fiercebiotech.com)
  • To evaluate the safety and toxicity of gefitinib and rapamycin, while secondarily determining time to tumor progression, overall survival and quality of life in recurrent GBM. (aacrjournals.org)
  • Glioblastoma is the most common and aggressive primary brain tumor with a dismal 5-10% survival rate at 5 years from diagnosis. (pharmiweb.com)
  • In this study, we performed gene expression profiling (DASL and RNA-seq) of formalin-fixed, paraffin-embedded tumor material from participants of the BELOB trial to identify patients with recurrent GBM who benefitted most from beva+CCNU treatment. (aacrjournals.org)
  • In addition to common variables, they provide data regarding the period of progression-free survival (PFS) following an aggressive lesionectomy for focally recurrent primary glioblastoma (T2) and the time the tumor took to recur since the previous surgery (T1). (thejns.org)
  • Using fluorescent visualization of the resection cavity, it was confirmed that there was subependymal and ependymal spread of the recurrent tumor along the lateral ventricle connecting the recurrence to the previous tumor site. (thejns.org)
  • Recurrent tumor can be found at the prior resection cavity, at a distant site, or anywhere else throughout the brain, including along the ependymal lining of the ventricles. (thejns.org)
  • These observations illustrate the possibility of improving survival and achieving a response in patients with end-stage recurrent glioblastoma by biasing the tumor toward anti-tumor immunologic response with a combination of NovoTTF-100A and TCCC, as well as the continuation of bevacizumab in order to limit dexamethasone use due to its global immunosuppressive effect on the patient. (harvard.edu)
  • By contrast, literally every targeting effort directed towards the most malignant and most frequent primary brain tumor, i.e. glioblastoma (GBM) has failed in the past [ 10 ]. (biomedcentral.com)
  • Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. (nih.gov)
  • Glioblastoma (GBM) is the most common and devastating primary malignant brain tumor in adults, encompassing 16% of all primary brain and central nervous system neoplasms ( 1 ). (nih.gov)
  • Most research on glioblastoma development, a complicated tumor of the brain with a poor prognosis, has focused on the gene transcription level, but scientists. (scienceblog.com)
  • Less than 10% of recurrent gliomas recur away from the original tumor site 1) . (neurosurgery.directory)
  • Besides a possible direct oncological effect, resampling of the recurrent tumor with detailed pathological and molecular analysis might have an impact on the development, testing, and validation of new salvage therapies 8) . (neurosurgery.directory)
  • The authors surveyed Swiss hospitals with comprehensive multidisciplinary neuro-oncology practices (neurosurgery, radiation therapy, medical neuro-oncology, and a dedicated neuro-oncology tumor board) about treatment recommendations for recurrent GBM. (neurosurgery.directory)
  • Methods We enrolled consecutive adult patients who had recurrent supratentorial WHO grade IV malignant glioma, confirmed on histopathological testing, with measurable disease (contrast-enhancing tumor of ≥1 cm and ≤5.5 cm in the greatest dimension). (neurocirurgiabr.com)
  • GROUP 1 (RESECTION CAVITY ADMINISTRATION): Patients undergo en block resection of their tumor (after confirming diagnosis) on day 1, followed by recombinant measles virus encoding human carcinoembryonic antigen (MV-CEA) administered into the resection cavity over 10 minutes. (careacross.com)
  • Patients undergo en block resection of their tumor with computer-assisted stereotactic techniques on day 5, followed by MV-CEA administered around the tumor bed. (careacross.com)
  • Despite improvements in the medical and surgical management of patients with glioblastoma, tumor recurrence remains inevitable. (elsevier.com)
  • Glioblastoma (GBM) is a primary malignant brain tumor with a dismal prognosis, partially due to our inability to completely remove and kill all GBM cells. (mdpi.com)
  • Immune responses triggered by the investigational cancer vaccine VBI-1901 correlate with the stabilization of tumor size in patients with recurrent glioblastoma (GBM), a common and aggressive brain cancer, according to new results from a Phase 1/2a clinical trial. (immuno-oncologynews.com)
  • Glioblastoma is an aggressive brain tumor affecting approximately 74,000 people worldwide annually. (firstwordpharma.com)
  • Tumor cell infiltration is a major mechanism of treatment escape in glioblastoma. (nyu.edu)
  • Study Start Date: May 2017 Study Type: Interventional Condition: Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System Glioblastoma Anaplastic Astrocytoma Intervention: Procedure: Laser Interstitial Thermal Therapy LITT delivered directly to the tumor by a neurosurgeon. (shine.com)
  • Glioblastoma, a type of glioma, is the most common adult primary brain cancer. (cnbc.com)
  • The main glioma types are astrocytoma (which includes glioblastoma), oligodendroglioma, ependymoma, and mixed glioma. (cnbc.com)
  • A phase 1 study including 61 patients with recurrent World Health Organization grade IV glioma. (mdedge.com)
  • There was no evidence of virus shedding or viral neuropathogenicity in the study, which included 61 patients with recurrent World Health Organization grade IV malignant glioma. (mdedge.com)
  • Background The prognosis of patients with recurrent World Health Organization (WHO) grade IV malignant glioma is dismal, and there is currently no effective therapy. (neurocirurgiabr.com)
  • Conclusions Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential. (neurocirurgiabr.com)
  • As noted in the abstract released today, subjects with recurrent or progressive grade III or IV glioma undergoing resection were intratumorally injected with 2 x 10 11 adenovirus (Ad) particles and received veledimex for 15 daily doses, beginning just prior to surgery. (firstwordpharma.com)
  • Bevacizumab combined with chemotherapy has recently shown promising efficacy in recurrent high-grade glioma. (regionh.dk)
  • A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-Naïve Subjects with Progressive High Grade Glioma Following Prior Therapy and Subjects with Newly Diagnosed Glioblastoma. (braintumor.org)
  • Glioblastomas are tumors that arise from astrocytes that make up the supportive tissue of the brain. (medindia.net)
  • this makes it difficult to draw firm conclusions from literature data as to the efficacy of a given treatment in recurrent brain tumors. (neurology.org)
  • Philipp Kickingereder, MD, from the University of Heidelberg Medical Center in Germany, and colleagues automatically extracted and analyzed 4,842 quantitative magnetic resonance imaging features from the multiparametric tumors of 172 patients with recurrent glioblastoma prior to bevacizumab treatment (allocated in a 2:1 ratio to a discovery and validation set). (empr.com)
  • Glioblastoma is among the most common and aggressive malignant primary brain tumors in humans. (globenewswire.com)
  • This engineered virus targets glioblastoma by gaining cell entry through the CD155 receptor, which is expressed on solid tumors. (mdedge.com)
  • The engineered virus gains entry via the CD155 receptor, which is upregulated in solid tumors such as glioblastomas and expressed in antigen-presenting cells. (mdedge.com)
  • One of the major difficulties in treating glioblastoma is its intrusive penetration into adjoining tissues, which prevents the complete surgical removal of the tumors from the brain, even with follow-up radiation and chemotherapy. (tgen.org)
  • Investigators conducted this phase III study under an approved IDE at 28 centers in the U.S., Europe , and Israel , enrolling 237 patients with glioblastoma tumors that had recurred or progressed after initial treatment. (fiercebiotech.com)
  • The data presented at SNO further validate TTF therapy as a potential treatment option for patients with recurrent glioblastoma tumors," said Asaf Danziger , chief executive officer of Novocure, the trial sponsor. (fiercebiotech.com)
  • This study will enroll 283 patients with newly diagnosed glioblastoma tumors. (fiercebiotech.com)
  • Glioblastomas with ependymal and/or subependymal spread are examples of diffuse infiltrative tumors that are incompletely seen on MRI. (thejns.org)
  • Thirty-three patients with primary disease and 9 patients with recurrent tumors were included. (biomedcentral.com)
  • Glioblastoma tumors are very susceptible to infection by CMV, with more than 90% of tumors expressing proteins from the virus. (immuno-oncologynews.com)
  • Advanced imaging techniques visualize macrophages in brain tumors in mouse models of glioblastoma. (neurosciencenews.com)
  • Glioblastomas represent 15% of all brain tumors. (wikipedia.org)
  • A small single-center non-randomized prospective study in patients with recurrent high grade gliomas treated with stereotactic fractionated radiotherapy (SFRT) showed a significant improvement in survival when AA-PET was integrated in target volume delineation, in comparison to patients treated based on CT/MRI alone. (whiterose.ac.uk)
  • Methods: This protocol describes a prospective, open label, randomized, multi-center phase II trial designed to test if radiotherapy target volume delineation based on FET-PET leads to improvement in progression free survival (PFS) in patients with recurrent glioblastoma (GBM) treated with re-irradiation, compared to target volume delineation based on T1Gd-MRI. (whiterose.ac.uk)
  • Discussion: This is a protocol of a randomized phase II trial designed to test a new strategy of radiotherapy target volume delineation for improving the outcome of patients with recurrent GBM. (whiterose.ac.uk)
  • All recurrent patients previously received radiotherapy, to a median dose of 52 Gy (range 36-62 Gy) at other institutions. (biomedcentral.com)
  • In this retrospective study, we evaluated treatment outcomes of hypofractionated stereotactic radiotherapy (HFSRT) in the management of recurrent GBM and report our single-center experience. (tumorijournal.com)
  • Salvage treatment options for recurrent GBM include surgery, radiotherapy in the form of stereotactic radiosurgery (SRS), fractionated stereotactic radiotherapy (FSRT) and/or systemic treatment (TMZ, alkylating agents, targeted therapies) ( 4 ). (tumorijournal.com)
  • Radiotherapy and/or radiosurgery for recurrent GBM is controversial. (medscape.com)
  • 1,2 ⇓ Many chemotherapeutic agents, either as single agents or in combination chemotherapy regimens, have been used to treat (recurrent) malignant gliomas. (neurology.org)
  • Six patients had been treated with reirradiation for recurrent disease before PCV chemotherapy. (neurology.org)
  • The results reported today expand on headline data from the trial presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in June 2010 , which suggested that TTF therapy may be as effective as the best available chemotherapy in extending overall survival of patients with recurrent GBM. (fiercebiotech.com)
  • The results from the randomized phase II BELOB trial provided evidence for a potential benefit of bevacizumab (beva), a humanized monoclonal antibody against circulating VEGF-A, when added to CCNU chemotherapy in patients with recurrent glioblastoma (GBM). (aacrjournals.org)
  • in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. (nih.gov)
  • Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation. (cdc.gov)
  • In summary, BCNU treatment appears to be a valuable therapeutic option for recurrent glioblastomas, where no other validated radio- and/or chemotherapy are available. (beds.ac.uk)
  • Although the optimal chemotherapeutic regimen for glioblastoma is not yet defined, several studies have suggested significant survival benefit from adjuvant chemotherapy. (medscape.com)
  • This Phase II clinical trial is specifically for patients with glioblastoma (first or second recurrence) that has recurred after treatments including surgery and radiation therapy, with or without chemotherapy. (ucsf.edu)
  • Brief Summary: Participant is being asked to take part in this study because they have glioblastoma or anaplastic astrocytoma (AA) that has relapsed (come back) after treatment and the study doctor thinks that it is in their best interest to receive chemotherapy for the disease. (shine.com)
  • In this study, patients with glioblastoma that had recurred after initial conventional therapy were randomized to treatment either with a TTFields device (NovoTTF-100A / Optune) or with their treating physician's choice of standard chemotherapy. (wikipedia.org)
  • Six-month PFS associated with relapsed or progressive glioblastoma is 9% to 21%, and median overall survival is 30 weeks or less, the authors noted. (medpagetoday.com)
  • A study of DSP-7888 dosing emulsion in combination with bevacizumab in patients with recurrent or progressive glioblastoma following initial therapy. (rush.edu)
  • ZIOP ), a biopharmaceutical company focused on new immunotherapies, today announced that it will present updated results from its Phase 1, multicenter, dose-escalation study of Ad-RTS-hIL-12 + orally administered veledimex in patients with recurrent or progressive glioblastoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 2-6 in Chicago. (globenewswire.com)
  • We conducted a prospective genomics-informed feasibility trial in adults with recurrent and progressive glioblastoma. (aacrjournals.org)
  • We performed a retrospective analysis of 35 patients with recurrent or progressive glioblastoma treated with 80 mg/m 2 BCNU on days 1 on 3 intravenously at our department for efficacy, toxicity and prognostic factors. (beds.ac.uk)
  • A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma. (springer.com)
  • All of the outcomes represented major improvement over historical data for patients with recurrent glioblastoma, according to an article published online in the Journal of Clinical Oncology . (medpagetoday.com)
  • In May of 2009, the FDA approved the use of bevacizumab (BEV) for recurrent glioblastoma (GBM) based on imaging and clinical responses demonstrated in Phase II clinical trials [ 1 - 6 ]. (hindawi.com)
  • That's when my neuro-oncologist, Barbara O'Brien, M.D. , told me about a clinical trial for pembrolizumab, an immunotherapy treatment that had been used for melanoma and was being tested for glioblastoma. (mdanderson.org)
  • But, what we try to look for, when a patient has recurrent disease, is to try to get them into a clinical trial either within our own group, or with some of our collaborating institutions nearby in Philadelphia or New York if it's a trial we don't have available. (onclive.com)
  • The goal of this clinical research study is to learn if BKM120 (buparlisib) can help to control glioblastoma and/or gliosarcoma. (mdanderson.org)
  • The study showed that DNX-2401 administered intratumorally provided clinical benefit and extended survival for patients with recurrent glioblastoma. (medindia.net)
  • DNAtrix's lead product, DNX-2401, is a conditionally replicative oncolytic adenovirus being evaluated in clinical trials for recurrent glioblastoma, a brain cancer for which there is neither a cure nor adequate treatment. (medindia.net)
  • Validating these initial findings in a clinical trial would represent a significant advance towards potential approval of I-124-CLR1404 for clinical use in the diagnosis and treatment of glioblastoma. (cnbc.com)
  • Treatment with NovoTTF-100A, as prescribed in the general clinical setting to patients with recurrent glioblastomas, offers favorable outcomes compared to historical patient data. (virtualtrials.com)
  • HealthDay News - A radiomic-based approach can be used to generate a prediction model for stratifying treatment outcome among patients with recurrent glioblastoma prior to bevacizumab treatment, according to a study published online October 10 in Clinical Cancer Research . (empr.com)
  • This study demonstrates the feasibility of using genome-wide molecular tests to guide treatment in recurrent glioblastoma," according to a scientific paper published today in Clinical Cancer Research , a journal of the American Association for Cancer Research (AACR). (tgen.org)
  • HAMPTON, N.J., May 31, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today presented positive results from the Company's randomized, double-blind Phase 2 study of RINTEGA® (rindopepimut) in patients with EGFRvIII-positive, recurrent glioblastoma at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. (fiercebiotech.com)
  • We have published hundreds of A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma news stories on BioPortfolio along with dozens of A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma Clinical Trials and PubMed Articles about A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma for you to read. (bioportfolio.com)
  • In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma Companies in our database. (bioportfolio.com)
  • We performed a pooled analysis of European Organization for Research and Treatment of Cancer (EORTC) trials on recurrent glioblastoma to validate existing clinical prognostic factors, identify new markers, and derive new predictions for overall survival (OS) and progression free survival (PFS). (nih.gov)
  • Clinical trial data have shown equivalent efficacy when compared to salvage chemotherapies in recurrent disease. (harvard.edu)
  • In this expansion cohort within a phase I study, the safety, tolerability, pharmacokinetics and clinical activity of GSK2256098 were evaluated in patients with recurrent glioblastoma. (deepdyve.com)
  • Because very little is known on the consistency of expression along the clinical course we here explored common drug targets in paired primary vs. recurrent GBM tissue samples. (biomedcentral.com)
  • The high incidence of dissimilar target expression status in clinical samples from primary vs. recurrent GBM suggests clinically relevant heterogeneity along the course of disease. (biomedcentral.com)
  • Molecular target expression, as determined at primary diagnosis, may not necessarily present rational treatment clues for the clinical care of recurrent GBM. (biomedcentral.com)
  • No evidence of relevant clinical antitumor activity against recurrent glioblastoma could be detected. (uni-regensburg.de)
  • In addition, multivariate analysis using Cox's proportional hazards model was used to evaluate the impact of clinical factors on OS-R after cytoreductive surgery in the patients with recurrent GBM. (researchsquare.com)
  • For recurrent glioblastoma, however, the clinical value of a second resection remains uncertain. (elsevier.com)
  • The chairs and speakers - all international experts in the glioblastoma field - will discuss the current standard of care for recurrent glioblastoma, novel treatment approaches, the role and biological mechanisms of the CD95/CD95 ligand (Fas/Fas ligand) pathway, as well as the rationale and clinical results of CD95 ligand/Fas ligand inhibition. (healthtechnologynet.com)
  • Checkpoint inhibitor asunercept, the company's lead immuno-oncology candidate, is in late-stage clinical development with PRIME (PRIority MEdicines) designation by the European Medicines Agency for the treatment of glioblastoma. (healthtechnologynet.com)
  • This clinical trial will evaluate the efficacy of MDNA55 in treating patients with recurrent glioblastoma. (ucsf.edu)
  • A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial. (aansneurosurgeon.org)
  • The goal of this clinical research study is to learn if the NeuroBlate system in combination with lomustine can help to control glioblastoma or anaplastic astrocytoma (AA) that has returned after treatment. (shine.com)
  • The first randomized clinical trial evaluating TTFields was published in November, 2014, and evaluated efficacy of this approach in patients with recurrent glioblastoma. (wikipedia.org)
  • Two earlier clinical studies had suggested a benefit of TTFields treatment in recurrent glioblastoma, but definitive conclusions could not be drawn due to their lack of randomized control-groups. (wikipedia.org)
  • Initial results of a Novocure-sponsored, phase-3, randomized clinical trial of TTFields in patients with newly diagnosed glioblastoma were reported in November, 2014, and published in December 2015. (wikipedia.org)
  • Because of the similarities in immunostaining of glial cells and glioblastoma, gliomas such as glioblastoma have long been assumed to originate from glial-type cells. (wikipedia.org)
  • Histologically proven diagnosis of glioblastoma (including giant cell glioblastoma and gliosarcoma). (centerwatch.com)
  • The authors sought to investigate the role of time to last recurrence on patient outcomes following aggressive repeat surgery for recurrent glioblastoma. (thejns.org)
  • Aim of the study: The purpose of this single arm phase II study is to evaluate safety and efficacy of ZK 219477 in the treatment of pre-treated, recurrent GBM patients. (knowcancer.com)
  • A literature overview on the feasibility and efficacy of the different irradiation modalities for recurrent glioblastoma along with considerations on areas of improvement are provided. (mdpi.com)
  • Again, if the patient hasn't been using Optune, I'd reopen that discussion with the patient because we do know that Optune does have efficacy in recurrent glioblastoma. (onclive.com)
  • 2 Cohort 2 2.1 Primary Objective To investigate the treatment efficacy of BKM120 in participants with recurrent GBM as measured by 6-month progressive-free survival (PFS6). (mdanderson.org)
  • This Phase II trial, being conducted at 10 NCI-designated cancer centers in the U.S., will compare the efficacy of I-124-CLR1404 positron emission tomography (PET) imaging in detecting glioblastoma with standard of care MRI based on pathology confirmation in approximately 36 patients. (cnbc.com)
  • Treatment with the recombinant poliovirus vaccine PVSRIPO in patients with recurrent glioblastoma can be delivered at a safe dose with efficacy that compares favorably with historical data, recently reported results of a phase 1, nonrandomized study suggest. (mdedge.com)
  • We conducted a phase II trial to evaluate the efficacy of dasatinib, a multitargeted tyrosine kinase inhibitor, for adults with recurrent glioblastoma (GBM). (nih.gov)
  • To assess the efficacy of temsirolimus and sorafenib in the treatment of recurrent glioblastoma in non-EIAC patients as measured by progression-free survival status at six months (PFS6). (clinicaltrialsgps.com)
  • The purpose of this study is to determine the efficacy of the combination of Bevacizumab and NovoTTF-100A in Bevacizumab naive (meaning have never received bevacizumab before) patients with recurrent glioblastoma (GBM) as measured by 6-month progression free survival. (careacross.com)
  • I. To determine the efficacy of the combination of bevacizumab and NovoTTF-100A in bevacizumab-naive patients with recurrent glioblastoma (GBM) as measured by 6-month progression-free survival (PFS6). (careacross.com)
  • Efficacy and safety of TMZ in recurrent GBM management has been investigated in many studies ( 9 - 10 - 11 ). (tumorijournal.com)
  • Few data exist about the efficacy of BCNU in patients with recurrent glioblastoma. (beds.ac.uk)
  • We evaluated the efficacy and safety of bosutinib, a tyrosine kinase inhibitor that potently inhibits Src and Abl, in patients with recurrent glioblastoma. (nyu.edu)
  • The drug was given accelerated FDA approval in 2009, and is often employed in patients with recurrent disease. (onclive.com)
  • I was then diagnosed with glioblastoma, the most aggressive form of brain cancer. (mdanderson.org)
  • Glioblastoma, the most common primary adult brain cancer, is rapidly life-threatening with most patients succumbing to the disease within 15 months after diagnosis despite aggressive surgery, radiation and chemotherapies. (cnbc.com)
  • Glioblastoma is an aggressive disease, with a median overall survival of only 15 months for newly diagnosed patients. (tgen.org)
  • Glioblastoma is an aggressive and molecularly heterogeneous cancer with few effective treatment options. (aacrjournals.org)
  • Glioblastoma (GBM) is the most aggressive central nervous system (CNS) primary malignancy in adults, with a median age at diagnosis of 65 years. (encyclopedia.pub)
  • Personalized prognostic tools and gene-based therapies may improve the survival and quality of life of patients suffering from glioblastoma, an aggressive and deadly form. (scienceblog.com)
  • Glioblastoma (GBM) is an aggressive primary human brain tumour that has resisted effective therapy for decades. (nature.com)
  • 90%) with GBM have locally recurrent disease despite aggressive management ( 2 , 3 ). (tumorijournal.com)
  • Glioblastoma, which is what Sen. John McCain has, is the most aggressive type of brain cancer. (cancerschmancer.org)
  • It was performed in Brazil and included 89 patients with glioblastoma, the most aggressive brain cancer type, where standard treatment had failed and patients had become unresponsive to standard care. (neonctech.com)
  • How long can Avastin® (bevacizumab) be taken for recurrent glioblastoma (rGBM)? (avastin.com)
  • How long can I take Avastin for recurrent glioblastoma (rGBM)? (avastin.com)
  • Avastin is approved to treat glioblastoma (GBM) in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM). (avastin.com)
  • Currently, no standard of care is established for recurrent or progressive GBM (rGBM) ( 9 ). (nih.gov)
  • Treatment options for recurrent GBM (rGBM) patiens are limited and the management remains a challenge. (encyclopedia.pub)
  • DNX-2401 has been well tolerated in patients with recurrent glioblastoma and survival has been prolonged compared to other therapies. (medindia.net)
  • Explain to patients that a targeted therapy improved response rate, progression-free survival, and overall survival in patients with recurrent glioblastoma, compared with historical standard therapy. (medpagetoday.com)
  • Patients with recurrent glioblastoma had dramatic improvement in response, progression-free survival (PFS), and overall survival compared with historical controls when treated with bevacizumab (Avastin) alone or in combination with irinotecan, data from a multicenter trial showed. (medpagetoday.com)
  • Eligible patients had glioblastoma in first or second relapse and disease progression confirmed by MRI. (medpagetoday.com)
  • Despite the therapeutic advances in neuro-oncology, most patients with glioblastoma ultimately experience local progression/relapse. (mdpi.com)
  • The initial studies, in 2009, for patients with recurrent glioblastoma, suggested that there was progression-free survival benefit, which may translate to improvement in quality of life. (onclive.com)
  • To investigate median progression free survival and overall survival of participants with recurrent GBM receiving treatment with BKM120. (mdanderson.org)
  • To our knowledge, this is the first report of a prospective profiling study in recurrent glioblastoma to show patients with extended time to progression following treatment with genomics-informed therapy," said Dr. Sara Byron, Research Assistant Professor in TGen's Integrated Cancer Genomics Division and the study's lead author. (tgen.org)
  • Interestingly, this putative EOR threshold closely approximates that reported for newly diagnosed glioblastomas, suggesting that for a subset of patients, the survival benefit of microsurgical resection does not diminish despite biological progression. (elsevier.com)
  • Brandes [ 5 ] reported about 40 patients with recurrent glioblastoma treated with BCNU and found a six months progression free survival of 17.5% and a median time to progression of 13.3 weeks. (beds.ac.uk)
  • NovoTTF-100A alternating electric fields therapy for recurrent glioblastoma: An analysis of patient registry data. (virtualtrials.com)
  • HACKENSACK, N.J., Jan. 29, 2019 /PRNewswire/ -- John Theurer Cancer Center at Hackensack Meridian Health Hackensack University Medical Center announced today that it is leading enrollment worldwide for WIZARD 201G, a global Phase 2 study in glioblastoma (GBM). (pharmiweb.com)
  • We retrospectively analyzed the treatment outcomes of 124 patients with recurrent GBM who were initially treated with the Stupp protocol in our institution between 2006 and 2019. (researchsquare.com)
  • HEIDELBERG, GERMANY / ACCESSWIRE / September 24, 2019 / Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it will be supporting a colloquium titled " Recurrent Glioblastoma Management: Challenges and Opportunities " at this year's ESMO Congress, held from September 27 to October 1 at the Fira Gran Via in Barcelona, Spain. (healthtechnologynet.com)
  • Recurrent glioblastoma in adults. (nih.gov)
  • Glioblastoma (GBM) has the highest mortality rate among primary brain tumours in adults and remains largely unmanageable with a life expectancy of about 6-24 months following diagnosis. (nature.com)
  • This will be an open label Phase II trial in adults with recurrent glioblastoma (GBM). (careacross.com)
  • VBI is currently testing the vaccine in adults with recurrent GBM in a multicenter, open-label Phase 1/2a trial ( NCT03382977 ). (immuno-oncologynews.com)
  • Avastin is indicated for the treatment of recurrent glioblastoma in adults. (avastin.com)
  • Overexpression of vascular endothelial growth factor (VEGF) in recurrent glioblastoma correlates with poor prognosis. (medpagetoday.com)
  • Patients with glioblastoma that express the EGFRvIII mutation typically have a worse prognosis than the overall glioblastoma population, including poor long-term survival. (fiercebiotech.com)
  • Validated scores to predict the prognosis after reoperation of a patient with a recurrent glioblastoma can help to select suitable candidates for surgery. (neurosurgery.directory)
  • The prognosis for patients with recurrent glioblastoma is still poor with a median survival between 3 and 6 months. (beds.ac.uk)
  • The authors present outcomes in 104 patients undergoing repeat surgery for focally recurrent glioblastoma with at least 95% resection and adjuvant treatment at most recent prior surgery. (thejns.org)
  • The relative benefit of repeat surgery for recurrent glioblastoma is unclear, in part due to the very heterogeneous nature of the patient population and the effect of clinician philosophy on the duration and aggressiveness of treatment. (thejns.org)
  • Given the lack of consensus on optimal management of recurrent GBM, knowledge of care patterns used for these patients and the criteria used to determine therapeutic strategy is germane to clinicians who care for these patients. (neurosurgery.directory)
  • The catheter delivers a genetically modified form of the poliovirus to treat glioblastoma. (cancerschmancer.org)
  • University of Texas Health Science Center at San Antonio) An experimental gene therapy essentially doubled the overall survival of patients with recurrent glioblastoma compared to the current standard of care, a researcher said Oct. 1 at the Cancer Therapy &Research Center at The University of Texas Health Science Center at San Antonio. (medworm.com)
  • Specifically, what proportion of contrast-enhancing recurrent glioblastoma tissue must be removed to improve overall survival and what is the neurological cost of incremental resection beyond this threshold? (elsevier.com)
  • For recurrent glioblastomas, an improvement in overall survival can be attained beyond an 80% EOR. (elsevier.com)
  • Studies using alkylating agents for recurrent GBM have conferred 6-month disease-free survival of 5-11 months, and median overall survival (OS) of 13-24% ( 6 - 7 - 8 ). (tumorijournal.com)
  • We concluded that the PCB + FTM combination as done in the current trial for patients with recurrent GBM after treatment with TMZ showed some benefit with regards to increased survival and that a Phase III trial is warranted. (virtualtrials.com)
  • The aim of this study was to investigate whether cytoreductive surgery prior to treatment with BEV contributes to prolongation of survival for patients with recurrent GBM. (researchsquare.com)
  • The primary objective of this trial is to determine the optimal dose and imaging time points of I-124-CLR1404 in subjects with newly diagnosed or recurrent glioblastoma. (cnbc.com)
  • One for newly diagnosed gbm and one for recurrent gbm. (virtualtrials.com)
  • These results mirror what we have seen in earlier RINTEGA studies conducted in newly-diagnosed patients, supporting our belief that RINTEGA will be an important treatment option for all patients with EGFRvIII-positive glioblastoma. (fiercebiotech.com)
  • Prognostic models have been developed to predict survival of patients with newly diagnosed glioblastoma (GBM). (nih.gov)
  • Reports about the application of carmustine (BCNU), one of the standard chemotherapeutic drugs in the treatment of newly diagnosed glioblastoma, in the recurrent situation are rare. (beds.ac.uk)
  • Histologically confirmed newly diagnosed glioblastoma. (braintumor.org)
  • This was the first large-scale trial in a decade to show a survival benefit for patients with newly diagnosed glioblastoma. (wikipedia.org)
  • The main purpose of this phase II study is to compare the effectiveness of treatment with DSP 7888 in combination with bevacizumab versus bevacizumab alone in patients with glioblastoma (GBM). (rush.edu)
  • March 4, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB) a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced enrollment of the first patient in its Phase II imaging trial of I-124-CLR1404 in patients with glioblastoma. (cnbc.com)
  • Bloch, O & Parsa, AT 2014, ' Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccination for Recurrent Glioblastoma: A Phase II, Single Arm Trial ', Neuro-Oncology , vol. 16, no. 5, pp. 758-759. (elsevier.com)
  • Optimal surgical resection for recurrent GBM may be hampered by large lesion size, critical location and unfavorable patient characteristics (poor performance status, older age, with comorbidities), and few patients are amenable to optimal surgery ( 14 , 15 ). (tumorijournal.com)
  • Recurrent Glioblastoma Treated with Recombinant Poliovirus. (neurocirurgiabr.com)
  • The Duke study recruited 61 patients with recurrent glioblastoma to try the poliovirus approach. (cancerschmancer.org)
  • This is a retrospective study of 40 adult patients with recurrent GBM treated between 2005 and 2009 at a single institution. (hindawi.com)
  • In the current study we examine cerebral blood volume and blood flow characteristics in 45 recurrent glioblastoma patients before and after treatment with bevacizumab. (springer.com)
  • We are honored that our study for recurrent glioblastoma was selected for an oral presentation at ASCO," said Frank Tufaro , PhD, CEO of DNAtrix. (medindia.net)
  • In this study, researchers want to see if adding nivolumab immunotherapy to re-radiation is safe and enhances treatment effectiveness for patients with recurrent GBM. (mskcc.org)
  • Here are the most relevant "A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma" Drugs and Medications that we have found in our database. (bioportfolio.com)
  • You can also find out about relevant A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma Drugs and Medications on this site too. (bioportfolio.com)
  • Newman, E. / Continuous intratumoral infusion of methotrexate for recurrent glioblastoma : A pilot study . (elsevier.com)
  • A very exciting phase 1 study on the treatment of recurrent glioblastoma was published in the New England Journal of Medicine . (medscape.com)
  • This study suggests the need to develop other treatment strategies for recurrent and TMZ-refractory GBM. (cdc.gov)
  • In this two-arm study, patients with histologically confirmed recurrent glioblastoma and ≤2 relapses, not previously treated with anti-vascular endothelial growth factor (VEGF) therapy, were administered oral bosutinib 400 mg daily. (nyu.edu)
  • Last year, he was diagnosed with a Grade IV glioblastoma and joined the next phase of the study. (cancerschmancer.org)
  • U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT03022578) titled 'Study of Laser Interstitial Thermal Therapy (LITT) in Recurrent Glioblastoma' on Jan. 13. (shine.com)
  • The first 457 patient with recurrent gbms who used the Novocure NovoTTF-100a therapy after it was FDA approved were analyzed to see how they did. (virtualtrials.com)
  • There is no consensus as to the standard of care as no therapeutic options have produced substantial survival benefit for recurrent glioblastoma s (GBMs) 6) 7) . (neurosurgery.directory)
  • Becker KP, Yu J (2012) Status quo-standard-of-care medical and radiation therapy for glioblastoma. (springer.com)
  • Additional radiation therapy ("re-radiation therapy") and bevacizumab are treatments used for people with recurrent glioblastoma (GBM). (mskcc.org)
  • Bevacizumab is often used in combination with radiation therapy as a treatment for patients whose glioblastoma grows during or after initial therapy. (mskcc.org)
  • To determine the effects of BKM120 on primary Glioblastoma(GBM) cell lines derived from participants and correlate with participant benefit from BKM120 treatment. (mdanderson.org)